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Finally, the editorial comment (6) addresses our work on
bioengineered septal occluder devices (7). These devices
showed rapid complete neo-endothelialization. The scaffold
can be heparin-coated in order to decrease further the
thrombogenicity of the implant surface. The basic concept
of this evolving device, however, is its biodegradability.
Especially in children with an expected implant persistence
of some 80 years, the degradation of the implant after
ingrowth and concurrent replacement by autologous host
tissue might be a concept not only to minimize foreign-body
reactions (such as perforations) but also to avoid the
potential for yet unknown long-term sequelae.
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Transcatheter Intracardiac
Device Implantation for Atrial
Level Defects and Thrombosis:
A Call for Randomized, Controlled Data
In their review of transcatheter device implants for atrial
septal defects (ASDs) and patent foramen ovale (PFO),
Krumsdorf et al. (1) present an instructive example of how
the cataloguing of non-standard indications for interven-
tion, treatment techniques, and outcome assessment con-
founds the management of patients with congenital heart
disease. Indeed, the lack of controlled data plagues the
device arena and prevents us from making evidence-based
treatment decisions in our patients with PFO and stroke.
Unfortunately, the accompanying editorial by Moore and
Levi (2) fails to call attention to the limitations of such
nonrandomized, uncontrolled data. As a result we are
concerned that erroneous conclusions will be drawn that can
have a negative impact on patient recruitment in ongoing
randomized, controlled clinical trials of device closure in
patients with PFO.
The investigators present a large collection of patients but
without a table of patient characteristics, making later
analysis against their defined end point of device-related
thrombosis all but impossible. The patient data that do exist
lack a standardized preprocedural assessment of prothrom-
botic risks (including major serologic determinants of arte-
rial and venous thrombosis such as antiphospholipid anti-
bodies and homocysteine as well as external determinants
such as cigarette and oral contraceptive use, thyroid or liver
disease, blood dyscrasias, obesity or trauma, valvular heart
disease, preprocedural palpitations, or atrial fibrillation).
Those deficiencies, combined with non-standardized im-
plant techniques, the use of postprocedural prothrombotic
therapy (protamine), non-standard, periprocedural anti-
platelet therapy, and variable device-specific follow-up pro-
tocols cloud the interpretation of the results.
The sensitivity and specificity of echocardiographically
detected device-related thrombosis is not defined for any of
the particular devices (each has different metallic composi-
tion and echocardiographic penetrance). In some cases,
device characteristics may limit detection of the 3- to 5-mm
thrombus that may be associated with neurologic events.
Both intra- and interobserver variability in recognizing
device-related thrombus are not discussed. Given the un-
certainty about diagnostic accuracy, because very few occur-
rences were seen in the trial, correlation of outcome to
causative factors becomes difficult at best.
Of particular concern is generalization from data ob-
tained in a practice setting that the investigators themselves
recognize is outside of current standards of care for device
implants (namely, use of protamine at procedure termina-
tion in the first 813 patients): 19 of 20 thrombotic events
occurred in this group. The applicability of such data for
today’s patients, who receive implants without the use of
postprocedure protamine, cannot be determined.
Moore and Levi (2) unfortunately generalize from the
investigators’ unsupported conclusions to recommend care
standards based upon differences in device design. In addi-
tion, the editorial comment does not place into context the
additional recognized device-related complications such as
cardiac erosion, death, valve interference, embolizations,
fractures, and proarrhythmia. We are deeply concerned by
these editorial recommendations. Clinical care standards
should be established only through the performance and
analysis of randomized controlled clinical trials and not
through anecdotal data as offered by Krumsdorf et al. (1).
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We find the results of Krumsdorf et al. (1) to be of
interest in its detail of the natural course of unusual
device-related, large-burden thrombosus in the now un-
common setting of protamine use. We consider other
associative relationships, as well as the editorial recommen-
dations of Moore and Levi (2), to be unsubstantiated.
Clinicians should not base management decisions in pa-
tients with PFO and stroke on such anecdotal and highly
selected data. We await the results of ongoing and future
randomized clinical trials to address these concerns.
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Incidence and Clinical Course of Thrombus
Formation on Atrial Septal Defect
and Patent Foramen Ovale Closure Devices
Krumsdorf et al. (1) present impressive data concerning the
risk of thrombus formation on closure devices for atrial
septal defects (ASDs) and patent foramen ovale (PFO) in
1,000 consecutive patients.
The vast majority of these patients were treated in the
Bethanien-Hospital where we worked together with Dr.
Sievert from July 1995 until he left our institution in June
2003. Until October 27, 2000, we shared the scientific
database for all patients who had received an atrial septal
implant. Therefore, we would like to add some information
on two of our patients who were apparently included in the
series of Krumsdorf et al. (1).
One PFO patient with an Amplatzer (AGA Medical
Corp., Golden Valley, Minnesota) occluder developed
thrombus on the left atrial disk of the device, which was
detected by transesophageal echocardiography (TEE) five
weeks after implantation (implanted January 26, 2000; TEE
date March 1, 2000). With heparinization and anticoagu-
lation, the further course was uneventful.
Another PFO patient suffered two strokes 5.7 years after
implantation of a Buttoned device (Custom Medical De-
vices, Amarillo, Texas). The TEE revealed a 10  7-mm
thrombus on the left atrial disk of the occluder (implanta-
tion date March 4, 1996; TEE date November 16, 2001).
The thrombus resolved after heparinization and anticoagu-
lation, and the further clinical course was uneventful. The
latter event was published as a case report (2).
We believe that these data might be clinically relevant,
not only because thrombus formation may occur early after
implantation of an Amplatzer device, but more importantly,
even after more than five years following defect closure.
Therefore, all investigators involved in the field of interven-
tional ASD closure have the obligation to follow their (own)
patients for an unlimited period of time.
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REPLY
We greatly appreciate the comments and suggestions by
Drs. Landzberg and colleagues, Massimo and colleagues,
Jux and Bertram, and Schräder regarding our recent paper
(1).
First, we absolutely share the opinion of Landzberg and
colleagues that randomized trials are superior to nonran-
domized trials! Conversely, nonrandomized trials are better
than no trials at all! And before a randomized trial can be
initiated we have to have an idea about what we are looking
for and what the incidence of a specific event like thrombus
formation might be. Dr. Landzberg and his colleagues know
very well how difficult it is to conduct a randomized trial in
catheter closure of intracardiac defects. Although the first
transcatheter atrial septal defect (ASD) closure was per-
formed more than 25 years ago, until today no randomized
trial has ever been started.
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